The Fly | APVO

Proprietary ADAPTIR™ Platform Technology: Aptevo's unique ADAPTIR™ platform allows for the creation of novel bispecific immunotherapeutics designed to precisely target and activate immune responses against cancer cells, offering a differentiated approach in oncology.

Clinical-Stage Oncology Pipeline: The company possesses multiple drug candidates in clinical development, such as APVO436 and APVO603, demonstrating tangible progress towards bringing new treatments to market and reducing the risk profile compared to purely preclinical biotechs.

Focus on Bispecific Immunotherapies: Aptevo specializes in bispecific antibodies, a rapidly advancing and high-potential area in cancer treatment that aims to enhance efficacy and overcome resistance mechanisms of existing therapies.

Clinical Trial Outcomes Uncertainty: The success or failure of drug candidates in clinical trials is highly uncertain.

Regulatory Approval Challenges: Obtaining necessary regulatory approvals for drug candidates is a lengthy and uncertain process.

Capital Raising and Liquidity Concerns: The company requires significant funding and may face challenges securing additional capital, leading to potential dilution.

Charts

Clinical Trial Outcomes Uncertainty: The success or failure of drug candidates in clinical trials is highly uncertain.

Regulatory Approval Challenges: Obtaining necessary regulatory approvals for drug candidates is a lengthy and uncertain process.

Capital Raising and Liquidity Concerns: The company requires significant funding and may face challenges securing additional capital, leading to potential dilution.

Today

Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone